Interplay of Oxidative Stress, Gut Microbiota, and Nicotine in Metabolic-Associated Steatotic Liver Disease (MASLD)

Antioxidants, Journal Year: 2024, Volume and Issue: 13(12), P. 1532 - 1532

Published: Dec. 14, 2024

Oxidative stress has been described as one of the main drivers intracellular damage and metabolic disorders leading to syndrome, a major health problem worldwide. In particular, free radicals alter lipid metabolism promote accumulation in liver, existing hepatic facet dysfunction-associated steatotic liver disease (MASLD). Recent literature highlighted how nicotine, especially if associated with high-fat diet, exerts negative effect on induction progression MASLD by upregulating inflammation increasing oxidative stress, abdominal fat lipolysis, lipogenesis. Moreover, considerable evidence shows central role intestinal dysbiosis pathogenesis impact nicotine-induced gut microbiome. This results an intricate network which stands at intersection point between microbiome, MASLD. The aim this review is delve into molecular mechanisms linking tobacco smoking MASLD, focusing microbiota modifications their development.

Language: Английский

---

Short-chain fatty acids in clinical practice: where are we?

Current Opinion in Clinical Nutrition & Metabolic Care, Journal Year: 2024, Volume and Issue: 28(2), P. 54 - 60

Published: Dec. 27, 2024

Purpose of review Once considered to have only local influences on the gut mucosa, short-chain fatty acids (SCFAs) now appear a much wider anti-inflammatory, immune-modulating, systemic effect. This article reviews recent evidence suggest clinical application this valued dietary substrate. Recent findings SCFAs act systemically through stimulation G protein receptors (GPRs) and inhibition histone deacetylases (HDACs). cause appetite suppression, reduce inflammation, improve insulin sensitivity, increase energy expenditure, promote mitochondrial function, stimulate satiety, blood pressure, cognitive function from various neurologic maladies. Summary Dietary strategies should be implemented provide beneficial substrate across wide spectrum disease conditions. Use prebiotic fiber or liquid supplements containing high SCFA-producing organisms as therapeutic targets for multiple metabolic, immunologic, neurodegenerative diseases.

Language: Английский

---

Metformin's modulation of gut microbiota and its implications for non-alcoholic fatty liver disease: A network pharmacology and molecular dynamics study

Human Gene, Journal Year: 2024, Volume and Issue: unknown, P. 201364 - 201364

Published: Dec. 1, 2024

Language: Английский

---

Potential application of the simulator of the human intestinal microbial ecosystem in metabolic dysfunction-associated steatotic liver disease

Minerva Biotechnology and Biomolecular Research, Journal Year: 2024, Volume and Issue: 36(4)

Published: Dec. 1, 2024

INTRODUCTION: Metabolic dysfunction-associated steatotic liver disease (MASLD) represents a growing global health concern, as it has become the most prevalent chronic condition worldwide, currently estimated to affect up 38% of adult population.EVIDENCE ACQUISITION: MASLD is complex impacting multiple systems, where systemic insulin resistance and related metabolic dysfunction play pathogenic role in its development progression disease. Despite prevalence, frequently under-recognized due lack reliable non-invasive biomarkers for accurate diagnosis staging, effective treatments remain elusive.EVIDENCE SYNTHESIS: Growing evidence suggests that gut microbiome significantly influences occurrence dysbiosis. The Simulator Human Intestinal Microbial Ecosystem® (SHIME®) sophisticated models mimics entire gastrointestinal tract, incorporating stomach, small intestine, different colon regions, each characterized by distinct physiology, anatomy, microbial community.CONCLUSIONS: SHIME® model emerges valuable tool exploring therapeutic approaches based on microbiota management. This simulator offers unique platform studying interactions within gut-liver axis. ongoing this technology expected yield further insights into strategies managing MASLD, improving patient outcomes through targeted interventions.

Language: Английский

---

Etiology-Dependent Microbiome Differences in Hepatocellular Carcinoma Development

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(24), P. 13510 - 13510

Published: Dec. 17, 2024

Chronic liver disease is characterised by persistent inflammation, tissue damage, and regeneration, which leads to steatosis, fibrosis, and, lastly, cirrhosis hepatocellular carcinoma (HCC). HCC, the most prevalent form of primary cancer, one leading causes cancer-related mortality worldwide. The gut microbiota plays a fundamental role in human physiology, disturbances its critical balance are widely recognised as contributors various pathological conditions, including chronic diseases, both infectious non-infectious nature. Growing interest research has recently shifted focus towards study intratumoural microbiota, referred “oncobiome”, can significantly impact development progression HCC. In this review, we discuss existing provide an overview influence on viral hepatitis, particularly shaping caused hepatitis B C viruses. We also explore microbial dysbiosis contribution silent dangerous non-alcoholic fatty disease. Additionally, address alcohol interaction with tracing pathway from inflammation cancer. review emphasises common etiologies carcinoma.

Language: Английский

---